As Oracle’s Executive Director Digital Trials Strategy, David Blackman has responsibility for aligning digital strategies and innovations with Oracle’s developing business needs. Within his role in Oracle’s Health Sciences Global Businesses Unit, David is responsible for creating and developing differentiating technology and business capabilities through development, partnerships and acquisitions that enhance clinical trial research and accelerate bringing drugs to market for our clients. Before joining Oracle in 2021, he served in the Corporate Development and Strategy group at PPD where he had responsibility for PPDs business innovation, leading and incubated cutting-edge business solutions resulting in the investment, development, integration and commercialization of digital and remote clinical trials capabilities.
Biomarkers, electronic health records (EHR), genomic data, imaging data, labs, social media, wearable sensors, and more provide enormous new sources of RWD that can aid in new discoveries for the quality, efficacy, and safety of new drug therapies.
As the industry focuses on creating a more holistic, inclusive experience, these three focus areas can help bridge the gap between patient, site, and clinical research administrators and help to modernize the clinical trial experience for all.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.